Finance
Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts
Published by Global Banking & Finance Review®
Posted on October 17, 2025
1 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on October 17, 2025
1 min readLast updated: January 21, 2026
Novo Nordisk hires Greg Miley as head of corporate affairs amid rising drug pricing pressures from the Trump administration.
LONDON/COPENHAGEN (Reuters) -Novo Nordisk has appointed U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, according to a statement he posted on LinkedIn, as the obesity drugmaker faces growing pressure from the Trump administration on drug pricing.
Miley, an American, is currently senior vice president of government affairs at U.S. pharmaceutical giant AbbVie. He posted the statement on LinkedIn on Friday and Novo Nordisk shared the statement with Reuters.
(Reporting by Maggie Fick in London and Stine Jacobsen in Copenhagen, Editing by Louise Heavens)
Corporate affairs refers to the management of a company's interactions with its stakeholders, including shareholders, employees, and the public, often focusing on communication and reputation management.
Drug pricing involves the determination of the cost of pharmaceuticals, influenced by factors such as production costs, market demand, and regulatory policies.
A pharmaceutical executive is a senior professional in the pharmaceutical industry responsible for strategic decision-making, overseeing operations, and ensuring compliance with regulations.
A LinkedIn statement is a public post or update shared on LinkedIn, often used by professionals to announce career changes, achievements, or company news.
The Trump administration sought to influence drug pricing through various policies aimed at reducing costs for consumers and increasing transparency in pharmaceutical pricing.
Explore more articles in the Finance category
